Biomedical

Vermeulens has released its market outlook report for the first quarter of 2019. Key points include:

The University of Missouri System broke ground on the $221 million NextGen Precision Health Institute in June of 2019. Located at the University of Missouri-Columbia, the five-story, 265,000-sf translational research facility will accommodate over 60 principal investigators working in collaboration with industry partners to develop innovative personalized medicine solutions.

The University of California, San Francisco opened the $275 million Precision Cancer Medicine Building (PCMB) in June of 2019. Located on UCSF's Mission Bay campus, the six-story facility consolidates outpatient services in a 170,000-sf structure with integrated cancer research labs, 63,000 sf of clinical space, 45 infusion bays, two accelerator vaults, and sophisticated imaging and diagnostic suites.

Northwestern University opened the $560 million Louis A. Simpson and Kimberly K. Querrey Biomedical Research Center in Chicago in June of 2019. Designed by Perkins+Will, the 12-story, 625,000-sf facility provides the Feinberg School of Medicine with integrated laboratory neighborhoods for the study of cancer, heart disease, and neurodegenerative disorders.

Aldevron will begin construction in August of 2019 on a 14-acre biologics campus in Fargo, N.D., where it is currently headquartered. The first phase comprises a two-story, 189,000-sf facility for the manufacture of plasmid DNA, proteins, mRNA, and antibodies. Increasing Aldevron’s GMP and GMP-Source™ production capacity up to tenfold, the structure will connect to the company's existing GMP facility and is expected to be fully operational by early 2021.

The Wistar Institute is partnering with University Place Associates to construct a 240,000-sf life science discovery hub in the University City district of Philadelphia. Designed to accelerate innovation by providing shared resources and critical infrastructure, the collaborative project will provide leasable laboratories and offices for biotech firms, research companies, and academic institutions.

Iovance Biotherapeutics entered into a lease agreement in May of 2019 to construct a 136,000-sf facility at the Philadelphia Navy Yard. Featuring modular processes for optimal scalability, the building will support commercial and clinical production of therapeutics based on tumor-infiltrating lymphocyte (TIL) technologies. The $125 million facility is slated for completion in mid-2021. Iovance will contribute approximately $75 million towards the cost of the building over three years for equipment and construction of the manufacturing suites.

The Rockefeller University dedicated the $500 million Stavros Niarchos Foundation–David Rockefeller River Campus in May of 2019 in New York. The 160,000-sf complex features the $300 million, 135,600-sf Marie-Josée and Henry R. Kravis Research Building which provides flexible labs, two amphitheaters, offices, conference rooms, a dining area, and outdoor terraces. The two-story, horizontally oriented structure was designed to enhance collaboration and can support over 600 scientific staff.

Chugai Pharmaceuticals will begin construction in August of 2019 on a $1.15 billion research and development center in Yokohama, Japan. Consolidating two labs currently sited in Gotemba and Kamakura, the facility will support drug discovery including the creation of therapies based on next-generation antibodies and synthetic macrocycles, also known as middle molecules. The pharmaceutical research center will leverage leading-edge automation processes and artificial intelligence technologies to accelerate the delivery of innovative medicines to patients worldwide.

WuXi Biologics began construction in May of 2019 on a 1.3 million-sf integrated manufacturing center in Chengdu, China. Meeting the criteria of both the U.S. Food and Drug Administration and the European Medicines Agency's GMP guidelines, the biologics hub will include both drug development and commercial manufacturing facilities. Offering an initial bioreactor capacity of 48,000 liters, the project is WuXi's twelfth drug substance manufacturing plant and will use the company's open-access and proprietary platforms.

The Rosalind Franklin Institute broke ground in May of 2019 on a £40 million campus hub in Harwell in the United Kingdom. The four-story, 58,000-sf facility will provide the government-funded research center with labs, instrumentation suites, offices, and interaction spaces to support leading-edge translational medicine programs.

Bayer broke ground in May of 2019 on the $150 million Cell Culture Technology Center in Berkeley, Calif. The 40,000-sf biopharmaceutical manufacturing facility will produce advanced therapeutics for the treatment of cancer and other diseases, enabling the company to expand its biologics development and launch capabilities. Fluor Corporation is providing a single point of responsibility for engineering, procurement, construction management, commissioning, qualification, validation, and integration of the project.

Colorado State University opened the $65 million C. Wayne McIlwraith Translational Medicine Institute in May of 2019 in Fort Collins. The 130,000-sf facility provides the College of Veterinary Medicine and Biomedical Sciences with equine and small animal surgery suites, flexible research labs, imaging rooms, instructional spaces, a surgical skills training lab, executive offices, and a 200-seat lecture hall.

Novo Nordisk's global production will be entirely powered by renewable energy by early 2020, with a ten-year goal of achieving zero carbon emissions from operations and transportation. The pharmaceutical company has made a $70 million investment in a 105-megawatt-dc solar energy installation to be built in Pender County, North Carolina.

The founding institutions of TMC3 have announced a new project team for their planned 37-acre translational research campus in Houston.